Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1961 1
1968 3
1973 1
1983 3
1985 1
1986 2
1988 2
1989 2
1992 2
1993 1
1994 3
1995 2
1996 2
1997 1
1998 2
1999 4
2000 5
2001 4
2002 5
2003 5
2004 1
2005 8
2006 3
2007 5
2008 7
2009 14
2010 10
2011 14
2012 8
2013 12
2014 16
2015 18
2016 14
2017 13
2018 14
2019 18
2020 19
2021 21
2022 12
2023 13
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

272 results

Results by year

Filters applied: . Clear all
Page 1
Catch me if you can: how AML and its niche escape immunotherapy.
Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M. Tettamanti S, et al. Among authors: dotti g. Leukemia. 2022 Jan;36(1):13-22. doi: 10.1038/s41375-021-01350-x. Epub 2021 Jul 23. Leukemia. 2022. PMID: 34302116 Free PMC article. Review.
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Liu E, et al. Among authors: dotti g. Leukemia. 2018 Feb;32(2):520-531. doi: 10.1038/leu.2017.226. Epub 2017 Jul 20. Leukemia. 2018. PMID: 28725044 Free PMC article.
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Ramos CA, et al. Among authors: dotti g. J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23. J Clin Oncol. 2020. PMID: 32701411 Free PMC article. Clinical Trial.
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, Ferrone CR, Pylayeva-Gupta Y, Yeh JJ, Liu R, Savoldo B, Ferrone S, Dotti G. Du H, et al. Among authors: dotti g. Cancer Cell. 2019 Feb 11;35(2):221-237.e8. doi: 10.1016/j.ccell.2019.01.002. Cancer Cell. 2019. PMID: 30753824 Free PMC article.
Interleukin-23 engineering improves CAR T cell function in solid tumors.
Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, Porterfield Kren N, Michaud D, Ahn S, Vincent B, Savoldo B, Pylayeva-Gupta Y, Zhang S, Dotti G, Xu Y. Ma X, et al. Among authors: dotti g. Nat Biotechnol. 2020 Apr;38(4):448-459. doi: 10.1038/s41587-019-0398-2. Epub 2020 Feb 3. Nat Biotechnol. 2020. PMID: 32015548 Free PMC article.
272 results